RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

RenovoRx, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.16+0.02 (+1.75%)

Close on Oct 19, 2026

Market cap: $54.87M
P/E (TTM): –
Dividend yield: –

RenovoRx, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	2.00	0	–	–	–	–
Stock-Based Compensation	1.27	1.17	1.08	0.64	0.15	0.03
Deferred Income Taxes	0	0	–	–	–	–
Change in Inventory	-0.19	0	–	–	–	–
Change in Accounts Payable	0.21	0.03	0.03	0.01	0.36	-0.38
Operating Cash Flow	-11	-9.13	-10	-8.81	-5.92	-3.53
Capital Expenditures	0.00	-0.01	–	–	–	–
Purchase of Investments	–	–	–	-8.00	–	–
Sale & Maturity of Investments	–	–	–	5.97	–	–
Investing Cash Flow	0.00	-0.01	2.03	-2.03	-0.02	–
Stock Issued	12	17	5.00	–	15	–
Financing Cash Flow	11	15	5.01	0.04	19	3.20
Net Change in Cash	-0.13	5.98	-3.22	-11	13	-0.33
Free Cash Flow	-11	-9.14	–	–	–	–
Income Taxes Paid	0.00	0.00	0.04	–	–	–
Interest Paid	0.02	0.02	0.01	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 84.4%
Operating margin: -685.2%
Net margin: -621.7%
Return on equity, FY2025: -225.6%

Financial strength

Current ratio: 5.74
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 503.1%

Valuation

P/E ratio: –
Price to sales: 27.77
Price to book: 6.11
Dividend yield: –